Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rituximab

- PMLiVE

AbbVie suspends Kaletra patent rights as COVID-19 drug trials advance

Drug and vaccine trials pick up speed as virus spreads

Roche Basel Switzerland

FDA okays Roche’s COVID-19 diagnostic test

Increases capacity for testing as coronavirus cases grow

- PMLiVE

EU grants approval for Venclyxto/Gazyvaro combo in CLL

Chemotherapy-free option for previously-untreated patients

- PMLiVE

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

Combination regimen didn't improve progression-free survival

Roche Basel Switzerland

China backs use of Roche’s Actemra for coronavirus

Anti-inflammatory drug will be used in patients with lung complications

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

AbbVie says Allergan takeover delayed by FTC verdict

Merger now likely to complete in second quarter rather than first

- PMLiVE

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October

- PMLiVE

AbbVie/Allergan merger faces renewed public opposition despite divestments

Consumer groups and public interest organisations raise new concerns

- PMLiVE

FDA sets June decision date for Tecentriq monotherapy in NSCLC

Aims for the first-line setting where Merck's Keytruda dominates

- PMLiVE

Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death

- PMLiVE

Botox strength bolsters Allergan ahead of AbbVie takeover

Speciality drugmaker posted a 6.6% sales increase in the last quarter

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links